ClinicalTrials.gg

Program

terallethrin

Also written as “M108”, “FG-M108” and “M108 monoclonal antibody”.

Its studies are mostly in Pancreatic Neoplasms · Stomach Neoplasms, led by FutureGen Biopharmaceutical (Beijing).

Furthest: phase 3, since Dec 11, 20233 company-led studies, 3 open or runningNext primary completion: Jan 11, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
FutureGen Biopharmaceutical (Beijing)33 open or runningphase 3since Dec 11, 2023May 12, 2021Jan 11, 2027phase 3 · NCT06177041

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 12, 2021First study: phase 1 study in Advanced Unresectable Solid TumorsFirst studyNCT04894825 · 152 planned · China
  2. Dec 11, 2023Phase 3 study in Stomach NeoplasmsNCT06177041 · 486 planned · China
  3. Jan 26, 2026Phase 3 study in Pancreatic NeoplasmsNCT07383922 · 524 planned · China

Ahead

  1. Jan 11, 2027Primary completion: phase 3 study in Stomach NeoplasmsNCT06177041
  2. Jun 30, 2030Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07383922

TargetBeta

CLDN18 →read by rule
“A monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), ”NCIt, by rule

Other programs on CLDN18

ProgramCompanyFurthest phaseStudies
zolbetuximabruleAstellas Pharmaphase 412
sonesitatug vedotinAstraZenecaphase 37
garetatug rezetecanJiangsu HengRui Medicinephase 37
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905ruleQilu Pharmaceuticalphase 36
tecotabart vedotinSino Biopharmaceuticalphase 36
arcotatug tavatecanruleInnovent Biologicsphase 35
Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1biokin-shanghai-biopharmaceutical-co-ltdphase 33
emaretamigruleAstellas Pharmaphase 33
Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200ruleSichuan Kelun Pharmaceuticalphase 23
Anti-Claudin 18.2 Antibody-drug Conjugate ASP546CruleAstellas Pharmaphase 22
givastomigrulei-mab-biopharma-us-limitedphase 22
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863AstraZenecaphase 21

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07383922Pancreatic Neoplasms · China3Not yet recruitingJun 30, 2030524
NCT06177041Stomach Neoplasms · China3RecruitingJan 11, 2027486
NCT04894825Advanced Unresectable Solid Tumors · China1RecruitingJul 30, 2024152

How it is read

Names in the registry

  • “M108”, 2 entries
  • “FG-M108”, 1 entry
  • “M108 monoclonal antibody”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.